Clopidogrel does not induce fibrinolysis in healthy subjects

Thrombosis Research

Volumn 114, Issue 2, 2004, Pages 97-100

  Taher, Taha H ^a   Stang, Linda ^b   Gordon, Philip A ^b   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Circadian changes; Clopidogrel; Fibrinolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; CLOPIDOGREL; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CIRCADIAN RHYTHM; CONTROLLED STUDY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CIRCADIAN RHYTHM; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; TICLOPIDINE;

EID: 4043139307     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.05.004     Document Type: Article

References (10)

1. Cannon C.P. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am. J. Cardiol. 90:2002;760-762
2. Mehta S.R., Yusuf S. Clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme: rationale, design, and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur. Heart J. 21:2000;2033-2041
3. Yusuf S., Mehta S.R., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 107:2003;966-972
4. Sharis P.J., Cannon C.P., Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. 129:1998;394-405
5. Gryglewski R.J., Korbut R., Swies J., et al. Thrombolytic action of ticlopidine: possible mechanisms. Eur. J. Pharmacol. 308:1996;61-67
6. Gryglewski R.J., Dupin J.P., Uracz W., et al. Thrombolysis by thienopyridines and their congeners. J. Physiol. Pharmacol. 51:2000;683-693
7. Kluft C., Jie A.F., Rijken D.C., et al. Daytime fluctuations in blood of tissue-type plasminogen activator (TPA) and its fast-acting inhibitor (PAI-1). Thromb. Haemost. 59:1988;329-332
8. Jovicic A., Mandic S. Circadian variations of platelet aggregability and fibrinolytic activity in healthy subjects. Thromb. Res. 62:1991;65-74
9. Gryglewski R.J., Uracz W., Swies J. Unusual effects of aspirin on ticlopidine induced thrombolysis. Thorax. 55(Suppl 2):2000;S17-S19
10. Urano T., Sakakibara K., Rydzewski A., et al. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb. Haemost. 63:1990;82-86